MedPath

Study of efficacy and tolerability of combination therapy with palonosetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in patients with cervical cancer.

Phase 2
Conditions
Cervical cancer
Registration Number
JPRN-UMIN000004962
Lead Sponsor
Kyoto University Graduate School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
Female
Target Recruitment
40
Inclusion Criteria

Not provided

Exclusion Criteria

# They had serious complication. (intestinal paralysis, lung fibrosis, diabetes mellitus, heart failure, myocardial infarction, angina pectoris, renal failure, psychiatric disorder, cerebrovascular accident, active gastric ulcer, active duodenal ulcer) # No known CNS metastasis # Patients who has a convulsive disorders that need anticonvulsants therapy # They had ascites or pleural effusion needs paracentesis treatment # Patients with obstruction of gastrointestinal tract,for example gastric outlet or ileus # Patients with vomiting or nausea (>= Grade2) # Hypersensitivity or severe drug allergy for Aloxi or other 5-HT3RA # Hypersensitivity or severe drug allergy for dexamethasone # Pregnant, breastfeeding or expecting woman # Patients judged inappropriate for this study by physicians

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The proportion of patients with complete response (CR: no vomiting and no use of rescue therapy ) in the delayed phase (24-120 hour after administration of nedaplatin and irinotecan)
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath